Investment Stage – Series A
PredictImmune aims to improve outcomes for patients by guiding treatment choices. Their vision is providing the tools that guide personalised medicine in inflammatory disease.
Spex Capital Ltd is an appointed representative of J8 Capital Management LLP which is authorised and regulated by the Financial Conduct Authority.
©2022 · Spex Capital
©2021 · Spex Capital